Clinical Trial: A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title:

Brief Summary: This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.

Detailed Summary:
Sponsor: Allergan

Current Primary Outcome:

  • Dose of Botulinum Toxin Used to Treat Cervical Dystonia [ Time Frame: 4 Years ]
  • Dose of Botulinum Toxin Used to Treat Blepharospasm [ Time Frame: 4 Years ]


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Botulinum Toxin Inter-injection Intervals [ Time Frame: 4 Years ]
  • Number of Participants with Adverse Events [ Time Frame: 4 Years ]
  • Annual Botulinum Toxin Dose per Patient [ Time Frame: 4 Years ]


Original Secondary Outcome: Same as current

Information By: Allergan

Dates:
Date Received: September 18, 2014
Date Started: August 2015
Date Completion:
Last Updated: January 6, 2016
Last Verified: January 2016